OHB-607 (Mecasermin rinfabate)

About Oak Hill Bio

Oak Hill Bio is a UK-based biotech with a unique 'relay' business model, acquiring and advancing late-stage rare disease programs abandoned by larger pharmaceutical companies. Its lead assets are rugonersen (OHB-724), an ASO for Angelman syndrome entering Phase 3, and OHB-607, a recombinant protein for bronchopulmonary dysplasia prevention in preemies, currently in Phase 2b with partner Chiesi. The company operates with a lean, asset-centric approach, aiming to de-risk development and deliver first- or best-in-class therapies to underserved patient populations.

Therapeutic Areas